Eledon reports Phase 1b data: tegoprubart prevents rejection with eGFR >70 in kidney transplant

Eledon Pharmaceuticals, Inc.

Data from 11 participants showed no graft loss or death; one mild T cell mediated rejection (Banff 1a) on day 99 treated successfully.
Aggregate mean eGFR above 70 mL/min/1.73m2 after day 90; no hyperglycemia, new onset diabetes, tremor, or CMV infection seen.
Phase 2 BESTOW trial comparing tegoprubart vs. tacrolimus underway; enrollment of ~120 participants expected to complete end of 2024.
One participant completed 1-year study with eGFR of 91 at day 374 and enrolled in Phase 2 open-label extension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.